S. Casula

Inter-Reader Agreement of ATA Sonographic Risk in Thyroid Nodules with Bethesda Category III Indeterminate Cytology

R. Castillo, M. I. L. Linares Valderrama, Marilyn A. Arosemena, 2021 .

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, The Lancet.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.

American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology.

R. Castillo, M. I. L. Linares Valderrama, Marilyn A. Arosemena, 2020, Thyroid : official journal of the American Thyroid Association.

Thyroid Hormone Replacement Therapy: Three ‘Simple’ Questions, Complex Answers

A. Bianco, S. Casula, 2012, European Thyroid Journal.

Use of Statins Among Patients Taking Levothyroxine: an Observational Drug Utilization Study Across Sites

W. H. Prieto, Matthew D Ettleson, A. Mayampurath, 2021, Journal of the Endocrine Society.

An unusual cause of mastoiditis that evolved into multiple ring-enhancing intracerebral lesions in a person with HIV infection.

S. Casula, L. Espinoza, J. Castro, 2007, The AIDS reader.

Thyroid Hormone Deiodinases and Cancer

A. Bianco, S. Casula, 2012, Front. Endocrin..

Are We Restoring Thyroid Hormone Signaling in Levothyroxine-Treated Patients With Residual Symptoms of Hypothyroidism?

Matthew D Ettleson, A. Bianco, S. Casula, 2023, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

False Positive Findings on I-131 WBS and SPECT/CT in Patients with History of Thyroid Cancer: Case Series

R. Kuker, S. Casula, Z. Hannoush, 2017, Case reports in endocrinology.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.